Linked Life Data

15041104

Source:http://linkedlifedata.com/resource/pubmed/id/15041104

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-3-25
pubmed:abstractText
To evaluate the efficacy, tolerability and safety of darifenacin, a once-daily M3) selective receptor antagonist (M3 SRA), in patients with overactive bladder (OAB).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0302-2838
pubmed:author
pubmed:issnType
Print
pubmed:volume
45
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
420-9; discussion 429
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
pubmed:affiliation
Département d'Urologie, Hôpital Tenon, 4 rue de la chine, 75020 Paris, France. fhaab@club-internet.fr
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Review, Research Support, Non-U.S. Gov't, Multicenter Study